Skip to main content
SGMT logo

Sagimet Biosciences Inc.

SGMTNASDAQHealthcareBiotechnology

$9.56Today:- (-)1Y +35.74%

As of Oct 26, 2026 close

Market cap
$507.77M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.50$11.45
Volume (live)
-
Avg. volume (3M)
1.48M

Sagimet Biosciences (SGMT) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Sagimet Biosciences used $45.65M of cash in operating activities. Free cash flow was −$45.65M.

Sagimet Biosciences Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sagimet Biosciences Inc. (SGMT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Depreciation & Amortization0.000.000.000.130.000.000.00
Stock Based Compensation6.455.294.991.881.900.782.99
Change in Working Capital-1.05-1.05-0.984.21-0.060.080.65
Change in Accounts Payable0.93-0.910.120.000.000.000.00
Change in Other Working Capital-1.980.15-1.104.210.130.080.65
Other Operating Activities-0.010.150.10-0.220.130.100.08
Net Cash from Operating Activities-45.65-42.44-23.77-24.49-21.71-10.42-10.55
Investing Activities
Purchases of Investments-106.86-108.09-19.62-41.450.000.000.00
Sales/Maturities of Investments111.4246.4032.209.440.000.000.00
Other Investing Activities0.000.000.000.000.000.02-0.03
Net Cash from Investing Activities4.56-61.6812.58-32.010.000.02-0.03
Financing Activities
Debt Repayment0.000.000.000.000.000.00-3.36
Common Stock Issued0.28105.7589.690.010.000.000.00
Other Financing Activities0.00-1.05-3.52-0.09-1.2568.8921.85
Net Cash from Financing Activities0.28104.8286.17-0.079.7468.8918.49
Summary
Net Change in Cash-40.820.7074.98-56.57-11.9758.497.91
Cash at Beginning of Period75.8475.140.1656.7368.7010.212.31
Cash at End of Period35.0275.8475.140.1656.7368.7010.21
Free Cash Flow-45.65-42.44-23.77-24.49-21.71-10.42-10.55

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Sagimet Biosciences Cash Flow

What is Sagimet Biosciences's free cash flow?

Sagimet Biosciences had negative free cash flow of $45.65M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Sagimet Biosciences pay dividends or buy back shares?

Sagimet Biosciences's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition